Driven by Biopharmaceutical Innovations and Gene Therapies, the market Booms Amidst Growing Incidence of Hemophilia and Von Willebrand Disease ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

Meanwhile, WuXi Vaccines, a subsidiary of WuXi Biologics, says it will sell a vaccine facility in Dundalk, Ireland, to the US drugmaker Merck & Co. for $521 million. WuXi Biologics says the sale ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

China's WuXi Biologics has announced plans to sell its vaccine facility in Ireland to U.S. pharmaceutical giant Merck & Co. for approximately USD 500 million. The decision comes ahead of potential U.S ...